Valuation: Rapid Therapeutic Science Laboratories, Inc.

Market Cap 85.73T 75.14T 69.46T 63.88T 1L 82.67L 1L 8L 3L 40.45L 3L 3L 1.39Cr P/E 2021
-16.6x
P/E 2022 -3.24x
Enterprise Value 39.16L 34.33L 31.73L 29.18L 55.06L 38Cr 55.95L 3.79Cr 1.49Cr 18Cr 1.47Cr 1.44Cr 64Cr EV / Sales 2021
93,97,88,53,933x
EV / Sales 2022 -
Free-Float
100%
Yield 2021 *
-
Yield 2022 -
15/23/15 Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
12/23/12 Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
31/23/31 Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
30/23/30 Rapid Therapeutic Science Laboratories, Inc. Auditor Raises 'Going Concern' Doubt CI
11/22/11 Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
13/22/13 Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
31/22/31 Rapid Therapeutic Science Laboratories, Inc. announced that it has received $0.35 million in funding CI
12/22/12 Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
17/22/17 Rapid Therapeutic Science Laboratories, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
16/22/16 Rapid Therapeutic Science Laboratories, Inc. Auditor Raises 'Going Concern' Doubt CI
28/22/28 Rapid Therapeutic Science Laboratories, Inc. announced that it has received $0.4 million in funding CI
18/22/18 Rapid Therapeutic Science Laboratories, Inc. announced that it has received $0.15375 million in funding from Sixth Street Lending, LLC CI
11/21/11 Rapid Therapeutics Science Laboratories Announces Launch of its New Facility Located in Addison, Tex CI
Manager TitleAgeSince
Chief Executive Officer 65 15/11/2019
Director of Finance/CFO 77 15/11/2019
Director TitleAgeSince
Director/Board Member 77 15/11/2019
Director/Board Member 65 15/11/2019
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-7.81% - - 1.9T
+1.21%+6.60%-7.45%-3.61% 1.35TCr
+1.23%+11.32%-26.78%-49.32% 526.88Cr
+1.06%+8.27%+1.69%-2.80% 472Cr
+6.67%+13.48%+15.79%-27.42% 406.7Cr
+2.51%+4.89%+6.61%-5.89% 374.65Cr
+2.10%+11.85%-2.90%-1.87% 356.93Cr
+4.42%+14.06%-0.86%+12.07% 338.98Cr
+1.74%+2.19%-11.61%-20.77% 242.09Cr
+1.79%+4.97%-0.13%+53.23% 186.11Cr
Average +2.27%+3.48%-2.85%-5.15% 473.1Cr
Weighted average by Cap. +2.22%+3.88%-4.38%-8.75%

Financials

2021 2022
Net sales 0 0 0 0 0 0.05 0 0.01 0 0.03 0 0 0.09 -
Net income -28.68L -25.14L -23.24L -21.37L -40.32L -28Cr -40.97L -2.78Cr -1.09Cr -14Cr -1.08Cr -1.05Cr -47Cr -17.95L -15.73L -14.54L -13.37L -25.23L -17Cr -25.64L -1.74Cr -68.16L -8.47Cr -67.39L -65.92L -29Cr
Net Debt 17.93L 15.72L 14.53L 13.36L 25.21L 17Cr 25.61L 1.74Cr 68.09L 8.46Cr 67.33L 65.86L 29Cr 38.31L 33.58L 31.04L 28.54L 53.86L 37Cr 54.72L 3.71Cr 1.45Cr 18Cr 1.44Cr 1.41Cr 62Cr
Logo Rapid Therapeutic Science Laboratories, Inc.
Rapid Therapeutic Science Laboratories, Inc is focused on developing potential commercial opportunities which involve the rapid application of therapeutics using inhaler technology. The Company is also focusing on manufacturing its own branded metered dose inhaler (MDI) under the inhaler brand name.
Employees
-